Selumetinib
|
|
|
- CAS-Nr.
- 606143-52-6
- Englisch Name:
- Selumetinib
- Synonyma:
- 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide;6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide;113183;CS-1912;AZD 6244;AZD-6224;umetinib;Smetinib;Smeitinib.;ARRY 142886
- CBNumber:
- CB81871940
- Summenformel:
- C17H15BrClFN4O3
- Molgewicht:
- 457.68
- MOL-Datei:
- 606143-52-6.mol
|
Selumetinib Eigenschaften
- Schmelzpunkt:
- >219°C (dec.)
- Dichte
- 1.69
- storage temp.
- -20°
- L?slichkeit
- Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 2 mg/ml)
- Aggregatzustand
- Beige powder.
- pka
- 14.20±0.10(Predicted)
- Farbe
- White
- Stabilit?t:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months.
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
  
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H317 |
Kann allergische Hautreaktionen verursachen. |
Sensibilisierung der Haut |
Kategorie 1A |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
| H318 |
Verursacht schwere Augensch?den. |
Schwere Augensch?digung |
Kategorie 1 |
Achtung |
![GHS hazard pictograms]() src="/GHS05.jpg" width="20" height="20" /> |
P280, P305+P351+P338, P310 |
| H373 |
Kann die Organe sch?digen bei l?ngerer oder wiederholter Exposition. |
Spezifische Zielorgan-Toxizit?t (wiederholte Exposition) |
Kategorie 2 |
Warnung |
|
P260, P314, P501 |
|
| Sicherheit |
| P262 |
Nicht in die Augen, auf die Haut oder auf die Kleidung gelangen lassen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P312 |
Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
|
Selumetinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Selumetinib (AZD6244; ARRY-142886) is an oral MEK inhibitor. In a randomized trial, NSCLC patients with wild-type KRAS were randomized to erlotinib
alone or combination therapy with selumetinib, while mutant KRAS patients were
randomized to selumetinib alone or combination therapy. The primary end points
were PFS for the KRAS wild-type cohort and objective response rate (ORR) for the
KRAS mutant cohort. Results were not impressive, with no PFS difference in the
KRAS wild-type arm (2.4 vs. 2.1?months) and no ORR difference in the KRASmutated subgroup (0% vs. 10%). A planned trial of selumetinib in combination
with the anti-PD-L1 antibody durvalumab has since been suspended (NCT03004105).
Definition
ChEBI: A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectiv
ly. It is a MEK1 and MEK2 inhibitor.
Trademarks
Koselugo
Allgemeine Beschreibung
Class: dual threonine/tyrosine kinase;
Treatment: children with NF1; Other name: AZD-6244, ARRY-142886;
Oral bioavailability = 62%;
Elimination half-life = 6.2 h;
Protein binding = 97.7%
Dosage
Selumetinib is characterized by a moderate oral
bioavailability (62%) and a relatively short half-life
(6.2 h), and these properties contribute to twice-daily
dosing regimen (25 mg dosage).
Selumetinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Selumetinib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 334)Lieferanten
- ARRY 142886
- AZD 6244
- Selumetinib
AZD624
- 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-car
- Selumetinib
- 5-(4-Bromo-2-chlorophenylamino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide
- 6-(4-Bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide
- SeluMatinib(5-[(4-BroMo-2-chlorophenyl)aMino]-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benziMidazole-6-carboxaMide
- AZD6244(SeluMetinib)
- AZD6244; ARRY142886
- SeluMetinib (AZD6244)
- Array142886
- AZD-6244(SeluMetinib)/AZD6244
- 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carbox
- AZD6244, ARRY-142886, ARRY-886
- 5-(4-BroMo-2-chlorophenylaMino)-4-fluoro-1-Methyl-1H-benziMidazole-6-carbohydroxaMic acid 2-hydroxyethyl ester
- 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide Selumetinib (AZD6244)
- AZD 6244
5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
- selumetinib (MEK inhibitor)
- Selumetinib, >=98%
- AZD-6224
- Selumetinib, 99%, a highly selective MEK1 inhibitor
- Selumetinib, Free BaseAZD6244ARRY-142886
- Selumetinib (AZD6244) Selumetinib
- ARRY-142886; SELUMETINIB;AZD-6244;ARRY142886
- AZD6244 (ARRY142886, Selumetinib)
- AZD6244 (Selumetinib,ARRY-142886)
- 113183
- CS-1912
- Selumetinib Base
- umetinib
- umetinib (AZD6244) SeL
- 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-
- Selumetinib USP/EP/BP
- Selumetinib D4
- 5-[(4-Bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
- 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide
- 5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzodimidazol-6-carboxamide
- Selumetinib API
- Smetinib
- Quinoxyfen Impurity 1
- Smeitinib.
- Selumetinib Impurity
- AZD6244, MEK1/2 inhibitor
- Selumetinib, 10 mM in DMSO
- 606143-52-6
- 60614-52-6
- C17H15BrClFN4O3
- MAPK
- Inhibitors
- Antineoplastic
- apis
- Aromatics
- Heterocycles
- Inhibitor
- Intermediates & Fine Chemicals
- Pharmaceuticals
- API
